- Home
- RAPT vs ITIC Comparison
RAPT vs ITIC Comparison
Compare RAPT & ITIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAPT
- ITIC
- Stock Information
- Founded
- RAPT 2015
- ITIC 1972
- Country
- RAPT United States
- ITIC United States
- Employees
- RAPT N/A
- ITIC N/A
- Industry
- RAPT Biotechnology: Pharmaceutical Preparations
- ITIC Specialty Insurers
- Sector
- RAPT Health Care
- ITIC Finance
- Exchange
- RAPT Nasdaq
- ITIC Nasdaq
- Market Cap
- RAPT 498.4M
- ITIC 517.1M
- IPO Year
- RAPT 2019
- ITIC N/A
- Fundamental
- Price
- RAPT $29.86
- ITIC $262.67
- Analyst Decision
- RAPT Strong Buy
- ITIC
- Analyst Count
- RAPT 8
- ITIC 0
- Target Price
- RAPT $46.75
- ITIC N/A
- AVG Volume (30 Days)
- RAPT 614.9K
- ITIC 31.5K
- Earning Date
- RAPT 11-11-2025
- ITIC 11-03-2025
- Dividend Yield
- RAPT N/A
- ITIC 6.06%
- EPS Growth
- RAPT N/A
- ITIC 25.49
- EPS
- RAPT N/A
- ITIC 17.49
- Revenue
- RAPT N/A
- ITIC $269,460,000.00
- Revenue This Year
- RAPT N/A
- ITIC N/A
- Revenue Next Year
- RAPT N/A
- ITIC N/A
- P/E Ratio
- RAPT N/A
- ITIC $15.16
- Revenue Growth
- RAPT N/A
- ITIC 15.27
- 52 Week Low
- RAPT $5.67
- ITIC $190.20
- 52 Week High
- RAPT $42.39
- ITIC $290.40
- Technical
- Relative Strength Index (RSI)
- RAPT 61.81
- ITIC 54.55
- Support Level
- RAPT $25.50
- ITIC $249.89
- Resistance Level
- RAPT $42.39
- ITIC $266.06
- Average True Range (ATR)
- RAPT 3.91
- ITIC 6.91
- MACD
- RAPT -0.18
- ITIC -0.94
- Stochastic Oscillator
- RAPT 30.92
- ITIC 43.33
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About ITIC Investors Title Company
Investors Title Co operates in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.